ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NBIX Neurocrine Biosciences Inc

137.54
0.00 (0.00%)
Pre Market
Last Updated: 09:12:15
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neurocrine Biosciences Inc NASDAQ:NBIX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 137.54 131.00 142.00 0 09:12:15

/C O R R E C T I O N -- Neurocrine Biosciences, Inc./

10/09/2015 7:12pm

PR Newswire (US)


Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Neurocrine Biosciences Charts.

In the news release, Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference, issued 10-Sep-2015 by Neurocrine Biosciences, Inc. over PR Newswire, the first paragraph, first sentence, should read "President" rather than "resident" as incorrectly transmitted by PR Newswire. The complete, corrected release follows:

Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference Live Audio Webcast Will be on September 17, 2015

SAN DIEGO, Sept. 10, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.

The live presentation takes place on Thursday, September 17 at 8:00am ET (5:00am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-global-healthcare-conference-300140271.html

SOURCE Neurocrine Biosciences, Inc.

Copyright 2015 PR Newswire

1 Year Neurocrine Biosciences Chart

1 Year Neurocrine Biosciences Chart

1 Month Neurocrine Biosciences Chart

1 Month Neurocrine Biosciences Chart

Your Recent History

Delayed Upgrade Clock